BioMediTech Research Groups


Group Leader: Professor Hannu Uusitalo


About Us

We are a multidisciplinary research group using methods of translational, clinical, epidemiological and personalized medicine. Our studies concentrate on eye and vision related illnesses and diagnostic methods for their treatment.

Research interests and expertise

  • Proteomics of the eye
  • Personalized medicine
  • In vitro and in vivo disease models for eye diseases
  • Imaging of the eye
  • Traffic vision and occupational vision
  • Eye and vision related epidemiological studies

Our areas of expertise are mass spectrometry-based proteomics, bioinformatics, clinical study design and implementation, in vitro and in vivo disease models and imaging technologies of the eye. We have several on-going clinical studies that involve ocular surface disease, dry eye, adverse drug reactions, glaucoma and refractive surgery. We are also studying age-related macular degeneration, diabetic retinopathy and retinopathy of prematurity.


  • We established The Center for Proteomics and Personalized Medicine PPM at the beginning of 2013 with Tekes’ FiDiPro funding.
  • We have identified several predictive biomarkers for different eye diseases to aid the diagnosis and evaluation of response to treatment in individual patients.
  • Together with our collaborators we have developed new imaging tools for diabetic retinopathy
  • We have been developing new glaucoma drugs
  • Research and Development Center for Ophthalmic Innovations (SILK) research network has been operating since 2009. SILK organizes public lectures, seminars, educational events and international SILK Elsemay Björn Symposium every year.


  • Proteomics facilities including mass spectrometers for biomarker discovery (TripleTOF 5600+) and targeted proteomics (QTRAP 6500+)
  • Clinical research laboratory for phase I-IV clinical trials
  • In vitro and in vivo eye disease models
  • Test laboratories for traffic and occupational vision

Collaboration offer and requests

Our proteomics facility can perform both biomarker discovery and targeted proteomics. We also have in vitro and in vivo disease models for research on ocular surface disease, dry eye, adverse drug reactions, age-related macular degeneration, glaucoma, diabetic retinopathy and retinopathy of prematurity.

For collaboration, contact group leader hannu.uusitalo(at) or ulla.aapola(at)

Major Publications

  1. Nättinen J, Jylhä A, Aapola U, Enríquez-de-Salamanca A, Pinto-Fraga J, López-Miguel A, González-García MJ, Stern ME, Calonge M, Zhou L, Nykter M, Uusitalo H, Beuerman R. Topical fluorometholone treatment and desiccating stress change inflammatory protein expression in tears. Ocul Surf. 2017 Sep 13. pii: S1542-0124(17)30038-1.
  2. Bartczak P, Fält P,Penttinen N, Ylitepsa P, Laaksonen L, Lensu L, Hauta-Kasari M, Uusitalo H. Spectrally optimal illuminations for diabetic retinopathy detection in retinal imaging. Optical review 2017, 24 (2), 105-116.
  3. Laatikainen L, Ojamo M, Rudanko S-L, Summanen P, Keinänen-Kiukaanniemi S, Tuomilehto J, Herrala S, Uusitalo H. Improving visual prognosis of the diabetic patients during the past 30 years based on the data of the Finnish Register of Visual Impairment. Acta Opthalmologica 2016 May 94(3):223-231.
  4. Mikhailova A, Jylhä A, Rieck J, Nättinen J, Ilmarinen T, Veréb Z, Aapola U, Beuerman R, Petrovski G, Uusitalo H, Skottman H. Comparative proteomics reveals human pluripotent stem cell-derived limbal epithelial stem cells are similar to native ocular surface epithelial cells. Scientific Reports 2015, Oct 1;5:14684.
  5. Uusitalo H, Chen E, Norbert Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88(3):329-36.
© 2019 | BioMediTech Finland. All rights reserved.